Onyx Biotec Limited IPO (Onyx Biotec Limited IPO ) Details

Onyx Biotec Limited, incorporated in May 2005, is a specialized pharmaceutical company focusing on the production of sterile water for injections and providing contract manufacturing for a wide range of pharmaceutical products. The company offers Dry Powder Injections and Dry Syrups to both Indian and international markets, meeting stringent quality standards to support the healthcare industry.

Core Business Operations

• Product Range: Onyx Biotec’s primary products include Sterile Water for Injections, Dry Powder Injections, and Dry Syrups. The company serves as a trusted contract manufacturer, helping pharmaceutical clients meet their production needs for sterile injectable products.
• Manufacturing Facilities: The company operates two manufacturing units in Solan, Himachal Pradesh.
  • Unit I: Produces up to 638,889 units of Sterile Water for Injections daily, catering to both high-volume and quality-sensitive requirements.
  • Unit II: Specializes in Dry Powder Injections with a capacity of 40,000 units per day, and Dry Syrups with a daily capacity of 26,667 units.

Clientele and Certifications

• Client Network: Onyx Biotec partners with over 100 clients, including major pharmaceutical companies like Hetero Healthcare, Mankind Pharma, Sun Pharma, Aristo Pharmaceuticals, Macleods Pharmaceuticals, and Reliance Life Sciences, among others.
• Quality Certifications: The company upholds ISO 9001:2015 and ISO 14001:2015 certifications for quality and environmental management, granted by ROHS Certification Private Limited, ensuring that all operations adhere to international standards.

Workforce and Competitive Strengths

• Experienced Team: As of July 31, 2024, Onyx Biotec employs 175 skilled professionals across various departments, contributing to its reputation for reliability and quality in pharmaceutical manufacturing.
• Market Position: With a strong commitment to quality, Onyx Biotec is recognized as one of the top pharmaceutical companies in India, supplying accessible and affordable products. Their expertise in sterile manufacturing processes and partnerships with leading pharmaceutical companies underscore their leadership in the market.

Onyx Biotec Limited remains focused on delivering high-quality, sterile pharmaceutical products to a global client base, ensuring access to essential medicines and supporting health initiatives worldwide.